OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

OKYO Pharma announced robust Phase 2 top-line results for urcosimod in neuropathic corneal pain (NCP), an indication currently lacking approved therapies. The trial demonstrated significant efficacy, with 75% of patients achieving over 80% pain reduction and a statistically significant average improvement of 5.5 points on the Visual Analogue Scale compared to 2.75 for placebo, alongside a strong effect size and no serious adverse events. Given these positive outcomes and the drug's Fast Track designation, OKYO plans immediate discussions with the FDA, positioning urcosimod as a promising potential first-in-class treatment for a significant unmet medical need.

Analysis

OKYO Pharma has reported highly positive and statistically significant top-line results from its Phase 2 trial of urcosimod for neuropathic corneal pain (NCP), a condition with no currently approved therapies. The trial demonstrated compelling efficacy, with 75% of patients achieving over 80% pain reduction and a mean improvement of 5.5 points on the Visual Analogue Scale (VAS) compared to 2.75 for placebo. The treatment effect was potent, as indicated by a Cohen-d metric greater than 1.2, and was particularly pronounced in patients with more severe disease. Importantly, the drug showed a favorable safety profile with no serious adverse events reported among the 18 enrolled patients. These results represent a significant de-risking event for the asset. The company's immediate plan to engage with the FDA, supported by the drug's existing Fast Track designation, positions urcosimod on a potentially accelerated path to becoming a first-in-class treatment for a significant unmet medical need.

Key Decisions for Investors

• The robust Phase 2 data significantly de-risks urcosimod and strengthens the investment case for OKYO as a potential leader in the untapped market for neuropathic corneal pain.
• Investors should focus on the upcoming meeting with the FDA as the next major catalyst, as guidance on the design of a pivotal Phase 3 trial and the path to market will be critical for valuation.
• While the results are strong, the small trial size of 18 patients necessitates a degree of caution, and confirmation in a larger, subsequent study will be required to fully validate the drug's profile.
• Given the drug's Fast Track designation and the high unmet need in NCP, consider the potential for an accelerated regulatory timeline and significant commercial opportunity if pivotal trials replicate these findings.